FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2505681192> ?p ?o ?g. }

• W2505681192 endingPage "2170" @default.
• W2505681192 startingPage "2159" @default.
• W2505681192 abstract "The goal of this study was to evaluate whether the blood pressure-lowering efficacy of fimasartan/amlodipine combination therapy was superior to that of fimasartan monotherapy after 8 weeks of treatment in patients with hypertension who had failed to respond adequately to fimasartan monotherapy.This trial was a randomized, double-blind, multicenter, Phase III clinical study. Patients who failed to respond after 4 weeks of treatment with 60 mg daily of fimasartan (sitting systolic blood pressure [SiSBP]) ≥140 mm Hg) were randomized to receive either daily fimasartan 60 mg or fimasartan/amlodipine 60 mg/10 mg. The primary efficacy end point was the change in SiSBP from baseline to week 8. Secondary end points included the change in SiSBP from baseline to week 4, the changes in sitting diastolic blood pressure from baseline to weeks 4 and 8, and the response rate (SiSBP <140 mm Hg or decrease in SiSBP ≥20 mm Hg) or control rate (SiSBP <140 mm Hg) at week 8. Treatment-emergent adverse events were also assessed.Of 143 patients randomized to treatment, 137 patients who had available efficacy data were analyzed. The mean age of patients was 59.1 (8.9) years, and 100 (73.0%) were male. Baseline SiSBP and sitting diastolic blood pressure were 150.6 (9.2) mm Hg and 91.7 (8.6) mm Hg, respectively. In the fimasartan/amlodipine combination group, a greater reduction in SiSBP from baseline to week 8 was observed compared with the fimasartan group (7.8 [13.3] mm Hg in the fimasartan group vs 20.5 [14.6] mm Hg in the fimasartan/amlodipine group; P < 0.0001). This reduction was observed after 4 weeks. The mean SiSBP changes from baseline to week 4 were 8.1 (15.8) mm Hg in the fimasartan group and 20.1 (14.7) mm Hg in the fimasartan/amlodipine group (P < 0.0001). At week 8, the response rate was significantly higher in the fimasartan/amlodipine (82.1%) group than in the fimasartan (32.9%) group (P < 0.0001). The control rate at week 8 was also higher in the fimasartan/amlodipine (79.1%) group than in the fimasartan (31.4%) group (P < 0.0001). Adverse drug reactions were observed in 9 patients (6.3%), with no significant differences between treatment groups. There were no serious adverse events associated with the study drugs.Fimasartan/amlodipine combination therapy exhibited superior efficacy in reducing blood pressure, with no increase in adverse drug reactions, compared with fimasartan monotherapy. ClinicalTrials.gov identifier: NCT02152306." @default.
• W2505681192 created "2016-08-23" @default.
• W2505681192 creator A5007158625 @default.
• W2505681192 creator A5015498389 @default.
• W2505681192 creator A5018311242 @default.
• W2505681192 creator A5023022774 @default.
• W2505681192 creator A5024282773 @default.
• W2505681192 creator A5024932707 @default.
• W2505681192 creator A5028102824 @default.
• W2505681192 creator A5036240200 @default.
• W2505681192 creator A5037630452 @default.
• W2505681192 creator A5040155349 @default.
• W2505681192 creator A5040288174 @default.
• W2505681192 creator A5040663056 @default.
• W2505681192 creator A5044591626 @default.
• W2505681192 creator A5044738299 @default.
• W2505681192 creator A5051877787 @default.
• W2505681192 creator A5053452214 @default.
• W2505681192 creator A5053631633 @default.
• W2505681192 creator A5054630096 @default.
• W2505681192 creator A5065796888 @default.
• W2505681192 creator A5067134266 @default.
• W2505681192 creator A5079395831 @default.
• W2505681192 creator A5080149524 @default.
• W2505681192 creator A5085895771 @default.
• W2505681192 creator A5086134599 @default.
• W2505681192 creator A5091627289 @default.
• W2505681192 date "2016-10-01" @default.
• W2505681192 modified "2023-10-16" @default.
• W2505681192 title "A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy" @default.
• W2505681192 cites W1966190328 @default.
• W2505681192 cites W1974719260 @default.
• W2505681192 cites W1975658002 @default.
• W2505681192 cites W1982002364 @default.
• W2505681192 cites W1985259248 @default.
• W2505681192 cites W2005000313 @default.
• W2505681192 cites W2006279996 @default.
• W2505681192 cites W2009820178 @default.
• W2505681192 cites W2025811675 @default.
• W2505681192 cites W2043244508 @default.
• W2505681192 cites W2054613686 @default.
• W2505681192 cites W2055067803 @default.
• W2505681192 cites W2059581639 @default.
• W2505681192 cites W2070116346 @default.
• W2505681192 cites W2072047048 @default.
• W2505681192 cites W2077978072 @default.
• W2505681192 cites W2087655403 @default.
• W2505681192 cites W2110020527 @default.
• W2505681192 cites W2110880027 @default.
• W2505681192 cites W2113158945 @default.
• W2505681192 cites W2114229079 @default.
• W2505681192 cites W2121647101 @default.
• W2505681192 cites W2153640315 @default.
• W2505681192 cites W2157629272 @default.
• W2505681192 cites W2172032309 @default.
• W2505681192 cites W2484483641 @default.
• W2505681192 cites W3150595609 @default.
• W2505681192 cites W4210524013 @default.
• W2505681192 cites W4236330958 @default.
• W2505681192 doi "https://doi.org/10.1016/j.clinthera.2016.07.008" @default.
• W2505681192 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27502326" @default.
• W2505681192 hasPublicationYear "2016" @default.
• W2505681192 type Work @default.
• W2505681192 sameAs 2505681192 @default.
• W2505681192 citedByCount "9" @default.
• W2505681192 countsByYear W25056811922016 @default.
• W2505681192 countsByYear W25056811922018 @default.
• W2505681192 countsByYear W25056811922019 @default.
• W2505681192 countsByYear W25056811922021 @default.
• W2505681192 countsByYear W25056811922022 @default.
• W2505681192 crossrefType "journal-article" @default.
• W2505681192 hasAuthorship W2505681192A5007158625 @default.
• W2505681192 hasAuthorship W2505681192A5015498389 @default.
• W2505681192 hasAuthorship W2505681192A5018311242 @default.
• W2505681192 hasAuthorship W2505681192A5023022774 @default.
• W2505681192 hasAuthorship W2505681192A5024282773 @default.
• W2505681192 hasAuthorship W2505681192A5024932707 @default.
• W2505681192 hasAuthorship W2505681192A5028102824 @default.
• W2505681192 hasAuthorship W2505681192A5036240200 @default.
• W2505681192 hasAuthorship W2505681192A5037630452 @default.
• W2505681192 hasAuthorship W2505681192A5040155349 @default.
• W2505681192 hasAuthorship W2505681192A5040288174 @default.
• W2505681192 hasAuthorship W2505681192A5040663056 @default.
• W2505681192 hasAuthorship W2505681192A5044591626 @default.
• W2505681192 hasAuthorship W2505681192A5044738299 @default.
• W2505681192 hasAuthorship W2505681192A5051877787 @default.
• W2505681192 hasAuthorship W2505681192A5053452214 @default.
• W2505681192 hasAuthorship W2505681192A5053631633 @default.
• W2505681192 hasAuthorship W2505681192A5054630096 @default.
• W2505681192 hasAuthorship W2505681192A5065796888 @default.
• W2505681192 hasAuthorship W2505681192A5067134266 @default.
• W2505681192 hasAuthorship W2505681192A5079395831 @default.
• W2505681192 hasAuthorship W2505681192A5080149524 @default.
• W2505681192 hasAuthorship W2505681192A5085895771 @default.
• W2505681192 hasAuthorship W2505681192A5086134599 @default.
• W2505681192 hasAuthorship W2505681192A5091627289 @default.
• W2505681192 hasBestOaLocation W25056811922 @default.
• W2505681192 hasConcept C126322002 @default.

• next